Myelofibrosis is a serious bone marrow disorder that disrupts your body's normal production of blood cells. The result is extensive scarring in your bone marrow, leading to severe anemia, weakness, fatigue, and often, an enlarged spleen and liver. Myelofibrosis is an uncommon type of chronic leukemia — a cancer that affects the blood-forming tissues in the body. Myelofibrosis belongs to a group of diseases called myeloproliferative disorders.
This is the first Australian study to explore the experiences of people living with four of the myeloproliferative neoplasm (MPN) subtypes for chronic myelofibrosis either primary or following an antecedent condition (n = 8), reported to the Australian Bone Marrow Transplant Registry between 1993 and 2005. During the 6 years 2000 to 2005, 40 HCTs were performed for CM compared with 17 in the 7 years 1993 to 1999. Twenty-four recipients (42%) were age 50 or over at transplantation.
In the past, the treatment of myelofibrosis has depended on the symptoms and degree of the low blood counts. A long-term remission is possible for some patients with bone marrow transplantation. Such treatment should be considered for younger patients and some others. Other treatment may involve:Blood transfusions and medicines to correct anemia, Radiation and chemotherapy, Medicines to target a genetic mutation, Splenectomy if swelling causes symptoms, or to help with anemia.